These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 11843248)

  • 1. Weekly cisplatin and oral etoposide as treatment for relapsed epithelial ovarian cancer.
    Meyer T; Nelstrop AE; Mahmoudi M; Rustin GJ
    Ann Oncol; 2001 Dec; 12(12):1705-9. PubMed ID: 11843248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment outcomes of paclitaxel for refractory or recurrent epithelial ovarian cancer patients in Thailand.
    Pitakkarnkul S; Tangjitgamol S; Srijaipracharoen S; Manusirivithaya S; Pataradool K; Prutthiphongsit W; Khunnarong J; Thavaramara T
    Asian Pac J Cancer Prev; 2013; 14(4):2421-7. PubMed ID: 23725151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bevacizumab combined with platinum-taxane chemotherapy as first-line treatment for advanced ovarian cancer: a prospective observational study of safety and efficacy in Japanese patients (JGOG3022 trial).
    Komiyama S; Kato K; Inokuchi Y; Takano H; Matsumoto T; Hongo A; Asai-Sato M; Arakawa A; Kamiura S; Tabata T; Takeshima N; Sugiyama T
    Int J Clin Oncol; 2019 Jan; 24(1):103-114. PubMed ID: 30030657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved survival trends in platinum-resistant patients with advanced ovarian, fallopian or peritoneal cancer treated with first-line paclitaxel/platinum chemotherapy: the impact of novel agents.
    Bamias A; Bamia C; Zagouri F; Kostouros E; Kakoyianni K; Rodolakis A; Vlahos G; Haidopoulos D; Thomakos N; Antsaklis A; Dimopoulos MA
    Oncology; 2013; 84(3):158-65. PubMed ID: 23296063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A combination of platinum and tamoxifen in advanced ovarian cancer failing platinum-based chemotherapy: results of a Phase II study.
    Benedetti Panici P; Greggi S; Amoroso M; Scambia G; Battaglia FA; Gebbia V; Salerno G; Paratore MP; Mancuso S
    Int J Gynecol Cancer; 2001; 11(6):438-44. PubMed ID: 11906546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Local radiation therapy for localized relapsed or refractory ovarian cancer patients with or without symptoms after chemotherapy.
    Fujiwara K; Suzuki S; Yoden E; Ishikawa H; Imajo Y; Kohno I
    Int J Gynecol Cancer; 2002; 12(3):250-6. PubMed ID: 12060445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Second-line Intraperitoneal Platinum-based Therapy Leads to an Increase in Second-line Progression-free Survival for Epithelial Ovarian Cancer.
    Boisen MM; Lesnock JL; Richard SD; Beriwal S; Kelley JL; Zorn KK; Edwards RP
    Int J Gynecol Cancer; 2016 May; 26(4):626-31. PubMed ID: 27051048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intra-peritoneal cisplatin combined with intravenous paclitaxel in optimally debulked stage 3 ovarian cancer patients: an Izmir Oncology Group study.
    Unal OU; Yilmaz AU; Yavuzsen T; Akman T; Ellidokuz H
    Asian Pac J Cancer Prev; 2014; 15(15):6165-9. PubMed ID: 25124592
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of neoadjuvant chemotherapy cycles prior to interval surgery in patients with advanced epithelial ovarian cancer.
    Colombo PE; Labaki M; Fabbro M; Bertrand M; Mourregot A; Gutowski M; Saint-Aubert B; Quenet F; Rouanet P; Mollevi C
    Gynecol Oncol; 2014 Nov; 135(2):223-30. PubMed ID: 25220627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epirubicin, Cisplatin, and Capecitabine for Primary Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer: Results of a Retrospective, Single-Institution Study.
    Sayal K; Gounaris I; Basu B; Freeman S; Moyle P; Hosking K; Iddawela M; Jimenez-Linan M; Abraham J; Brenton J; Hatcher H; Earl H; Parkinson C
    Int J Gynecol Cancer; 2015 Jul; 25(6):977-84. PubMed ID: 25962114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Weekly cisplatin with oral etoposide: a well-tolerated and highly effective regimen in relapsed ovarian cancer.
    Verborg WA; Campbell LR; Highley MS; Rankin EM
    Int J Gynecol Cancer; 2008; 18(2):228-34. PubMed ID: 17511798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant platinum-based chemotherapy in patients with epithelial ovarian cancer: prognostic factors and final outcome.
    Grivas A; Lianos E; Internos I; Papaxoinis G; Tselepatiotis E; Ziras N; Athanasiou AE
    J BUON; 2010; 15(4):647-51. PubMed ID: 21229624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Salvage chemotherapy in recurrent platinum-resistant or refractory epithelial ovarian cancer with Carboplatin and distearoylphosphatidylcholine pegylated liposomal Doxorubicin (lipo-dox®).
    Khemapech N; Oranratanaphan S; Termrungruanglert W; Lertkhachonsuk R; Vasurattana A
    Asian Pac J Cancer Prev; 2013; 14(3):2131-5. PubMed ID: 23679331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gemcitabine and carboplatin treatment in patients with relapsing ovarian cancer.
    Sufliarsky J; Chovanec J; Svetlovska D; Minarik T; Packan T; Kroslakova D; Lalabova R; Helpianska L; Horvathova D; Sevcik L; Spacek J; Laluha A; Tkacova V; Malec V; Rakicka G; Magdin D; Jancokova I; Dorr A; Stresko M; Habetinek V; Koza I
    Neoplasma; 2009; 56(4):291-7. PubMed ID: 19473054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of prolonged oral etoposide in patients with ovarian cancer refractory to or relapsing within 12 months after platinum-containing chemotherapy.
    de Wit R; van der Burg ME; van den Gaast A; Logmans A; Stoter G; Verweij J
    Ann Oncol; 1994 Sep; 5(7):656-7. PubMed ID: 7993845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First-line intraperitoneal cisplatin-paclitaxel and intravenous ifosfamide in Stage IIIc ovarian epithelial cancer.
    Zylberberg B; Dormont D; Madelenat P; Daraï E
    Eur J Gynaecol Oncol; 2004; 25(3):327-32. PubMed ID: 15171311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adenosine triphosphate-based chemotherapy response assay predicts long-term survival of primary epithelial ovarian cancer.
    Li LY; Kim SW; Nam EJ; Lee J; Kim S; Kim YT
    Int J Gynecol Cancer; 2019 Feb; 29(2):334-340. PubMed ID: 30718314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preliminary experience with salvage weekly paclitaxel in women with advanced recurrent ovarian carcinoma.
    Dunder I; Berker B; Atabekoglu C; Bilgin T
    Eur J Gynaecol Oncol; 2005; 26(1):79-82. PubMed ID: 15755007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Weekly cisplatin and daily oral etoposide is highly effective in platinum pretreated ovarian cancer.
    van der Burg ME; de Wit R; van Putten WL; Logmans A; Kruit WH; Stoter G; Verweij J
    Br J Cancer; 2002 Jan; 86(1):19-25. PubMed ID: 11857006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bevacizumab plus low-dose metronomic oral cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer.
    Sánchez-Muñoz A; Mendiola C; Pérez-Ruiz E; Rodríguez-Sánchez CA; Jurado JM; Alonso-Carrión L; Ghanem I; de Velasco G; Quero-Blanco C; Alba E
    Oncology; 2010; 79(1-2):98-104. PubMed ID: 21079407
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.